April 30, 2026 |
Expanded access programs (EAPs) play a multifaceted role in the drug development life cycle, serving as a critical bridge between clinical trials and commercial availability.

To read the whitepaper in full, please see here: Enhancing the EAP Experience for HCPs & Patients | Uniphar
Latest Content from Uniphar
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,…
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position…
[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s…
[Dublin, 05 February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global…
Isaac Batley, an experienced CEO with 35 years’ experience within healthcare and pharmaceutical communications, joins Uniphar to spearhead its medical communications division.
Healthcare services business, Uniphar, has developed its full-service offering that harnesses Uniphar’s 57 years in the industry delivering specialist services to more than 200 international clients across 180 countries.
